JP7540953B2 - Ｅｒｂｂ受容体阻害剤 - Google Patents

Ｅｒｂｂ受容体阻害剤 Download PDF

Info

Publication number
JP7540953B2
JP7540953B2 JP2020562751A JP2020562751A JP7540953B2 JP 7540953 B2 JP7540953 B2 JP 7540953B2 JP 2020562751 A JP2020562751 A JP 2020562751A JP 2020562751 A JP2020562751 A JP 2020562751A JP 7540953 B2 JP7540953 B2 JP 7540953B2
Authority
JP
Japan
Prior art keywords
compound
mmol
cancer
her2
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523159A5 (https=
JP2021523159A (ja
Inventor
リー，チェンタオ
チョン，ウェイ
ワン，ジアビン
ゼン，チンベイ
ツイ，ホンチュン
ヤン，チェンファン
チャン，シャオリン
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2021523159A publication Critical patent/JP2021523159A/ja
Publication of JP2021523159A5 publication Critical patent/JP2021523159A5/ja
Priority to JP2024007265A priority Critical patent/JP7810734B2/ja
Application granted granted Critical
Publication of JP7540953B2 publication Critical patent/JP7540953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020562751A 2018-05-08 2019-05-08 Ｅｒｂｂ受容体阻害剤 Active JP7540953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007265A JP7810734B2 (ja) 2018-05-08 2024-01-22 Ｅｒｂｂ受容体阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/085998 2018-05-08
CN2018085998 2018-05-08
PCT/CN2019/085949 WO2019214634A1 (en) 2018-05-08 2019-05-08 Erbb receptor inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007265A Division JP7810734B2 (ja) 2018-05-08 2024-01-22 Ｅｒｂｂ受容体阻害剤

Publications (3)

Publication Number Publication Date
JP2021523159A JP2021523159A (ja) 2021-09-02
JP2021523159A5 JP2021523159A5 (https=) 2022-05-13
JP7540953B2 true JP7540953B2 (ja) 2024-08-27

Family

ID=68467752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562751A Active JP7540953B2 (ja) 2018-05-08 2019-05-08 Ｅｒｂｂ受容体阻害剤
JP2024007265A Active JP7810734B2 (ja) 2018-05-08 2024-01-22 Ｅｒｂｂ受容体阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007265A Active JP7810734B2 (ja) 2018-05-08 2024-01-22 Ｅｒｂｂ受容体阻害剤

Country Status (15)

Country Link
US (2) US10822334B2 (https=)
EP (2) EP4410291A3 (https=)
JP (2) JP7540953B2 (https=)
KR (1) KR102806778B1 (https=)
CN (4) CN112266384B (https=)
AR (1) AR117424A1 (https=)
AU (1) AU2019267959B2 (https=)
BR (1) BR112020022829A2 (https=)
CA (1) CA3099315A1 (https=)
DK (1) DK3814341T3 (https=)
ES (1) ES2977196T3 (https=)
MX (2) MX2020011868A (https=)
PT (1) PT3814341T (https=)
TW (2) TWI858848B (https=)
WO (1) WO2019214634A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024050653A (ja) * 2018-05-08 2024-04-10 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ受容体阻害剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
TWI879751B (zh) * 2020-03-23 2025-04-11 印度商皮埃企業有限公司 3-被取代的苯基脒化合物及其製備和用途
CA3194724A1 (en) * 2020-10-05 2022-04-14 Dana-Farber Cancer Institute, Inc. Potent and selective inhibitors of her2
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
IL312004A (en) * 2021-10-20 2024-06-01 Hoffmann La Roche Crystalline forms of quinazoline derivatives, their preparation, assembly and use
CN114262327B (zh) * 2021-12-30 2023-01-03 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
CN118715216A (zh) * 2022-03-28 2024-09-27 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025051148A1 (zh) * 2023-09-05 2025-03-13 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
CN117658818B (zh) * 2023-11-03 2025-02-07 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511603A (ja) 2001-11-03 2005-04-28 アストラゼネカ アクチボラグ 抗腫瘍薬としてのキナゾリン誘導体
JP2005515176A (ja) 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
JP2007505874A (ja) 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
JP2008531666A (ja) 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 抗腫瘍剤としてのインダゾリルアミノキナゾリン誘導体
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物
JP2009515988A (ja) 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
TWI858848B (zh) 2018-05-08 2024-10-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511603A (ja) 2001-11-03 2005-04-28 アストラゼネカ アクチボラグ 抗腫瘍薬としてのキナゾリン誘導体
JP2005515176A (ja) 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
JP2007505874A (ja) 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
JP2008531666A (ja) 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 抗腫瘍剤としてのインダゾリルアミノキナゾリン誘導体
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのｅｒｂＢ受容体チロシンキナーゼ阻害剤としての４−（１Ｈ−インダゾール−５−イル］アミノ）キナゾリン化合物
JP2009515988A (ja) 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bernard BARLAAM et al.，Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，2008年，vol.18, no.6，p.1799-1803

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024050653A (ja) * 2018-05-08 2024-04-10 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ受容体阻害剤
JP7810734B2 (ja) 2018-05-08 2026-02-03 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｅｒｂｂ受容体阻害剤

Also Published As

Publication number Publication date
US20210009587A1 (en) 2021-01-14
MX2023008954A (es) 2023-08-18
CN111587248A (zh) 2020-08-25
DK3814341T3 (da) 2024-04-22
US11447492B2 (en) 2022-09-20
CN111662289A (zh) 2020-09-15
MX2020011868A (es) 2021-02-26
CN111747953B (zh) 2021-05-07
KR20210013071A (ko) 2021-02-03
ES2977196T3 (es) 2024-08-20
US20200317669A1 (en) 2020-10-08
KR102806778B1 (ko) 2025-05-12
PT3814341T (pt) 2024-04-11
TW202015690A (zh) 2020-05-01
JP2021523159A (ja) 2021-09-02
EP3814341A4 (en) 2022-01-05
AU2019267959A1 (en) 2020-11-26
US10822334B2 (en) 2020-11-03
EP3814341B1 (en) 2024-03-20
AU2019267959B2 (en) 2024-06-06
JP7810734B2 (ja) 2026-02-03
CN112266384A (zh) 2021-01-26
JP2024050653A (ja) 2024-04-10
WO2019214634A1 (en) 2019-11-14
CA3099315A1 (en) 2019-11-14
TW202344253A (zh) 2023-11-16
AR117424A1 (es) 2021-08-04
EP3814341A1 (en) 2021-05-05
EP4410291A3 (en) 2024-08-14
EP4410291A2 (en) 2024-08-07
TWI811358B (zh) 2023-08-11
TWI858848B (zh) 2024-10-11
BR112020022829A2 (pt) 2021-02-02
CN111747953A (zh) 2020-10-09
CN112266384B (zh) 2022-09-23

Similar Documents

Publication Publication Date Title
JP7810734B2 (ja) Ｅｒｂｂ受容体阻害剤
JP7326305B2 (ja) 医薬化合物
JP6505131B2 (ja) イミダゾ［４，５−ｃ］キノリン−２−オン化合物および癌の処置におけるそれらの使用
JP7725511B2 (ja) ４－アミノキナゾリン化合物
JP2021522281A (ja) がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤
CN102482277A (zh) 表皮生长因子受体抑制剂及治疗障碍的方法
IL293107A (en) Adenosine receptor antagonist compounds
JP2025515285A (ja) 大環状複素環及びその使用
US20220411422A1 (en) Erbb receptor inhibitors
CN115707704B (zh) 氘代稠合三环类化合物及其组合物和用途
RU2810215C2 (ru) Ингибиторы рецепторов erbb
HK40114639A (en) Erbb receptor inhibitors
HK40045061B (en) Erbb receptor inhibitors
HK40045061A (en) Erbb receptor inhibitors
HK40046084B (en) Erbb receptor inhibitors
HK40046084A (en) Erbb receptor inhibitors
HK40037928A (en) Erbb receptor inhibitors
HK40037928B (en) Erbb receptor inhibitors
HK40028318A (en) Erbb receptor inhibitors
HK40028142A (en) Erbb receptor inhibitors
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240815

R150 Certificate of patent or registration of utility model

Ref document number: 7540953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150